11 HURLEY ST., CAMBRIDGE, MA
Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Announces First Quarter 2026 Results and Business Updates
Annual Report to Security Holders
Change in Accountant - Ernst & Young Dismissed, PwC Appointed
U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Financial Results, Press Release
Announces Third Quarter 2025 Results and Business Updates
Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Q1
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement
Confidential Treatment Order
SEC Staff Correspondence